SEC Form SD filed by Alcon Inc.

$ALC
Ophthalmic Goods
Health Care
Get the next $ALC alert in real time by email
SD 1 alconformsd31dec2023.htm SD Document

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549



FORM SD
SPECIALIZED DISCLOSURE REPORT



Alcon Inc.
(Exact name of the registrant as specified in its charter)

Switzerland001-31269
(State or other jurisdiction of
incorporation or organization)
(Commission File Number)


Rue Louis-d'Affry 6, 1701 Fribourg, Switzerland
(Address of principal executive offices)



Royce Bedward
Senior Vice President, General Counsel & Corporate Secretary
Chemin de Blandonnet 8, 1214 Vernier, Geneva, Switzerland
Tel: +41 58 911 20 00
(Name and telephone number, including area code, of the
person to contact in connection with this report.)




Check the appropriate box to indicate the rule pursuant to which this form is being filed:

_X_ Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2023.
___ Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended ______.





Section 1. Conflict Minerals Disclosure
Item 1.01 Conflict Minerals Disclosure and Report
In accordance with Rule 13p-1 under the Securities Exchange Act of 1934, Alcon Inc. has filed this Specialized Disclosure Form (Form SD) and the associated Conflict Minerals Report. Both reports are posted and publicly available at the Alcon corporate website: https://www.alcon.com/about-us/responsible-business-practice.

Item 1.02 Exhibit
The Conflict Minerals Report is attached as Exhibit 1.01.

Section 2. Resource Extraction Issuer Disclosure
Item 2.01 Resource Extraction Issuer Disclosure and Report
Not applicable.

Section 3. Exhibits
Item 3.01 Exhibits
Exhibit No.     Description






SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.
ALCON INC.
Date:May 29, 2024By:/s/ Royce Bedward
Name: Royce Bedward
Title: Authorized Representative
Date:May 29, 2024By:/s/ Ed McGough
Name: Ed McGough
Title: Authorized Representative

Get the next $ALC alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ALC

DatePrice TargetRatingAnalyst
3/25/2025Neutral → Buy
BofA Securities
1/24/2025$108.00 → $106.00Buy
Needham
1/10/2025Neutral → Buy
Redburn Atlantic
12/17/2024$103.00 → $108.00Buy
Needham
11/12/2024Buy
Needham
10/10/2024Sell → Neutral
Redburn Atlantic
9/10/2024Sector Perform → Outperform
RBC Capital Mkts
7/15/2024$65.00 → $85.00Underweight → Equal-Weight
Morgan Stanley
More analyst ratings

$ALC
Press Releases

Fastest customizable press release news feed in the world

See more
  • Alcon Announces CE Mark Approval and Commercialization of Clareon Vivity IOL in Europe, Expanding Visual Possibilities

    Clareon Vivity IOL provides an extended range of vision from distance to functional near with a monofocal visual disturbance profile1-3µ‖ Vivity, the world's leading EDOF, is now available on Alcon's Clareon material, providing presbyopia correction with exceptional† clarity and predictable refractive outcomes1,4-7 CE Marked countries will begin commercial rollout of Clareon Vivity and Clareon Vivity Toric from early Q2 2025; also available in AutonoMe automated pre-loaded delivery system in Q3 20258 Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that Vivity®, the most widely implanted9 extended depth of focus (EDOF)

    $ALC
    Ophthalmic Goods
    Health Care
  • Alcon Agrees to Acquire LENSAR, Inc.

    Acquisition of ALLY Robotic Cataract Laser Systems strengthens Alcon's cataract equipment and technology portfolioNext generation technology will be expanded globally, improving the efficiency of cataract surgery GENEVA and ORLANDO, Fla., March 24, 2025 (GLOBE NEWSWIRE) -- Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, and LENSAR, Inc. (NASDAQ:LNSR), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today announced the companies have entered into a definitive merger agreement through which Alcon intends to acquire LENSAR. The acquisition includes ALLY Robotic Cataract Laser Treatment Sy

    $ALC
    $LNSR
    Ophthalmic Goods
    Health Care
    Medical/Dental Instruments
  • Alcon to Host 2025 Capital Markets Day

    Alcon (SIX/NYSE:ALC), the global leader in eye care, will host its 2025 Capital Markets Day on March 27, 2025, beginning at 8:00 a.m. CT. A live webcast of the event will be available at the following link: https://investor.alcon.com/news-and-events/events-and-presentations/event-details/2025/Alcons-2025-Capital-Markets-Day-2025-6w85_Spqte/default.aspx. Those wishing to participate should register and log on approximately 10 minutes before the start of the webcast. About Alcon Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our Surgical an

    $ALC
    Ophthalmic Goods
    Health Care

$ALC
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ALC
SEC Filings

See more

$ALC
Leadership Updates

Live Leadership Updates

See more
  • Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board

    Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of the Scientific Advisory BoardOculis established a CHF 50 million flexible loan facility with funds and accounts managed by BlackRock ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS))) ("Oculis" or the "Company"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the results from its 2024 Annual General Meeting

    $ALC
    $NARI
    $OCS
    $RXST
    Ophthalmic Goods
    Health Care
    Medical/Dental Instruments
    Biotechnology: Pharmaceutical Preparations

$ALC
Financials

Live finance-specific insights

See more
  • Alcon Reports Full-Year 2024 Results, with Strong Top-line and Earnings Growth and Record Cash Generation

    Full-year 2024 sales of $9.8 billion, up 5%, or up 6% constant currency1 (cc) Full-year 2024 diluted EPS of $2.05, up 5% on a reported basis, or up 11% cc; core diluted EPS2 of $3.05 up 11% on a reported basis, or up 16% cc Generated record $2.1 billion of cash from operations in full-year 2024; record free cash flow3 of $1.6 billion, up 120% Announced share repurchase authorization to offset dilution from associate equity incentive plans Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and twelve month periods ending December 31, 2024. For the fourth quarter of 2024, sales were $2.5

    $ALC
    Ophthalmic Goods
    Health Care
  • Alcon Reports Solid Third-Quarter 2024 Results, including Double-Digit Earnings Growth and Record Cash Generation

    Third-quarter 2024 sales of $2.4 billion, up 6% on a reported and constant currency1 (cc) basis Third-quarter 2024 diluted EPS of $0.53, up 29%, or 32% cc; core diluted EPS2 of $0.81, up 23%, or 25% cc Generated $1.6 billion of cash from operations in the first nine months of 2024; record free cash flow3 of $1.3 billion, up $704 million, or 119% Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and nine month periods ending September 30, 2024. For the third quarter of 2024, sales were $2.4 billion, an increase of 6% on a reported and constant currency basis1, as compared to the same quarte

    $ALC
    Ophthalmic Goods
    Health Care
  • Alcon Reports Second-Quarter 2024 Results with Strong Growth in Implantables and Contact Lenses

    Record Q2 2024 sales of $2.5 billion, up 3%, or 6% constant currency1 (cc) Q2 2024 diluted EPS of $0.45, up 32%, or 47% cc; core diluted EPS2 of $0.74, up 7%, or 15% cc H1 2024 cash from operations of $871 million; free cash flow3 of $667 million, up $478 million, or 253% Received U.S. FDA clearance of Unity VCS/CS and PDUFA date for AR-15512 of May 30th, 2025 Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and six month periods ending June 30, 2024. For the second quarter of 2024, sales were $2.5 billion, an increase of 3% on a reported basis and 6% on a constant currency basis1, as

    $ALC
    Ophthalmic Goods
    Health Care

$ALC
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more